Inbrain Neuroelectronics has announced that it has raised US$18.8 million in series A funding for its artificial intelligence (AI)-powered, graphene neuromodulation technology.
According to a company press release, Inbrain’s technology harnesses the power of graphene, a two-dimensional material first isolated in 2004 made of a lattice of carbon atoms only one atom thick.
Inbrain states that its less-invasive graphene electrodes take advantage of some of the properties of graphene to enable ultra-high signal. The Inbrain system’s machine learning software detects therapy-specific biomarkers to deliver highly focused, adaptive neuromodulation therapy that is personalised for each patient.
The funding will be used to advance Inbrain’s first-in-human clinical programme, aiming to establish the safety of graphene as the new standard of care for neurotechnology devices, the company claims.
“At Inbrain, our mission is to improve the lives of patients with brain-related diseases, who are forced to live alone with their conditions. Less invasive and more intelligent neuroelectronic technologies like ours could provide safer therapies that are upgradable and adaptive in real time, to empower these patients and improve the outcomes that matter to them,” said Inbrain Neuroelectronics co-founder and CEO Carolina Aguilar.
“Graphene technology has matured and is ready for the next challenge. This investment is an important stepping stone toward our goal of transforming the way neurological disorders are treated,” added Jose Garrido, co-founder and chief scientific officer of In.